Expiration Date: June 9, 2005

RELEASE DATE:  November 10, 2003

RFA Number:  RFA-AI-04-001 (This RFA has been renewed with modifications, see RFA-AI-05-028)
                           (See addenda NOT-AI-04-048 and NOT-AI-04-036)

Department of Health and Human Services (DHHS)

National Institutes of Health (NIH) 

National Institute of Allergy and Infectious Diseases (NIAID) 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 
National Institute of Dental and Craniofacial Research (NIDCR) 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 
National Institute of Neurological Disorders and Stroke (NINDS) 

No. 93.855, Immunology, Allergy, and Transplantation Research, NIAID
No. 93.856, Microbiology and Infectious Diseases Research, NIAID
No. 93.866, Arthritis, Musculoskeletal and Skin Diseases Research, NIAMS
No. 93.121, National Institute of Dental and Craniofacial Research, NIDCR
No. 93.847, Diabetes, Endocrinology and Metabolism Research, NIDDK
No. 93.848, Digestive Diseases and Nutrition Research, NIDDK
No. 93.849, Kidney Diseases, Urology and Hematology Research, NIDDK
No. 93.853, Extramural Research Programs in the Neurosciences and Neurological 
Diseases, NINDS

LETTER OF INTENT RECEIPT DATE: One month prior to application receipt date.

APPLICATION RECEIPT DATE: Applications will be accepted MONTHLY on the 9th of 
each month. The last receipt date will be June 9, 2004.


o Purpose of this RFA
o Research Objectives
o Mechanism of Support
o Funds Available
o Eligible Institutions
o Individuals Eligible to Become Principal Investigators
o Special Requirements 
o Where to Send Inquiries
o Letter of Intent
o Submitting an Application
o Supplementary Instructions
o Peer Review Process
o Review Criteria
o Receipt and Review Schedule
o Award Criteria
o Required Federal Citations


The National Institute of Allergy and Infectious Diseases (NIAID), the 
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), 
the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 
the National Institute of Neurological Disorders and Stroke (NINDS), and the 
National Institute of Dental and Craniofacial Research (NIDCR) of the National 
Institutes of Health (NIH) invite investigator-initiated research applications 
for mechanistic studies in clinical trials of: (1) immunomodulatory 
interventions for immune system mediated diseases, including, but not limited 
to: asthma and allergic diseases; graft failure in solid organ, cell, tissue 
and stem cell transplantation; and chronic inflammatory, autoimmune, and 
immunodeficiency diseases; and (2) preventative and therapeutic, vaccines for 
non-HIV/AIDS infectious diseases, including NIAID Category A, B, and C agents 
of bioterrorism and emerging/re-emerging infectious diseases. This Request for 
Applications (RFA) is a continuation and modification of RFA AI-02-003 

In order to review and confer awards to grant applications received in 
response to this RFA in a timely fashion, without delay of the parent clinical 
trial, NIAID has developed a pilot project in collaboration with the NIH 
REVIEW/AWARD.  All applications responding to this RFA will be subject to this 
hyperaccelerated review/award process.  Highly meritorious applications 
selected for funding under this RFA will receive their awards thirteen weeks 
after the application receipt date.  Holidays and other circumstances may 
alter this schedule slightly.


In December 1996, NIAID convened a workshop at which leading basic and 
clinical immunologists discussed the role the NIH should play in current and 
projected clinical trials for various immune mediated diseases.  It was 
considered likely that clinical trials of many new immunologic interventions 
would be supported by the pharmaceutical/biotechnology industry.  However, 
gaps in both knowledge and in research effort were identified which represent 
opportunities for the NIH to contribute to progress in this area.

There was agreement that the mechanisms underlying immunologic interventions 
are poorly understood even in cases where efficacy has been shown (e.g., 
allergen immunotherapy, treatment of multiple sclerosis with interferons, 
Copolymer-I, and in other immunomodulatory regimens under development).  In 
addition, clinical trials supported by industry and other sources including 
NIH often do not include studies of underlying mechanisms.  There was 
consensus that high priority should be given to the utilization of patient 
samples from clinical trials in immunologic diseases for studies of the basic 
underlying mechanisms of therapeutic effect, immunologic function, and disease 

There was also agreement that the usual time required for grant review and 
funding is often incompatible with the time-line of a clinical trial.  
Specifically, when a clinical protocol is finalized (which is required for 
applications submitted under this RFA), investigators are often ready to begin 
as soon as Institutional Review Board approval is obtained.  NIAID was 
encouraged to develop a means of responding rapidly to opportunities to study 
underlying mechanisms in order to facilitate collaborations with industry-
supported clinical trials.

These recommendations were strongly supported by a large number of 
investigators who participated in NIAID focus groups in the winter/spring of 
REVIEW/AWARD were developed in order to implement these recommendations and 
exploit the research opportunities identified.  Based on the successful 
implementation of RFA AI-98-006, the follow-up RFAs RFA-AI-00-005, AI-01-001, 
AI-02-003 and the Pilot, the current RFA is being issued to continue this effort.

The objective of this RFA is to support mechanistic research studies in 
clinical trials of immunomodulatory interventions for: (1) immune system 
mediated diseases, including: asthma and allergic diseases; graft failure in 
solid organ, cell, tissue and stem cell transplantation; and chronic 
inflammatory, autoimmune diseases, and immunodeficiency diseases; and (2) 
vaccines for the prevention and treatment of non-HIV/AIDS infectious diseases, 
including NIAID Category A, B and C agents of bioterrorism and emerging/re-
emerging infectious diseases (see list of agents at 

Specifically, the goal of this RFA is the inclusion of patients and 
utilization of patient samples from such clinical trials for the evaluation of 
immunologic and other relevant parameters in order to study and define the 
underlying immunological mechanisms of the intervention or vaccine, the 
mechanisms of disease pathogenesis, surrogate/biomarkers of disease activity 
and therapeutic effect, and mechanisms of human immunologic function.  
Such studies are not part of the parent clinical trial, and are commonly 
referred to as substudies or ancillary studies.  The parent clinical trial 
must have independent financial support and will NOT receive support under 
this RFA. Proposed mechanistic studies associated with clinical trials 
supported by industry are particularly encouraged but clinical trials 
supported by any source, public or private, are eligible. Clinical trials 
of any phase (i.e., Phases I-IV) are eligible.  Examples of relevant 
research include, but are not limited to, the following:

o  Quantitation of disease-related, autoreactive or alloreactive lymphocytes 
using methods such as MHC/peptide tetramers, chimeric antibodies, or very 
early activation antigens.

o  Analysis of autoreactive or alloreactive cells by PCR for expression of 
genes implicated in immunity or inflammation, or by flow cytometry for cell 
surface markers that identify functions (e.g., cytokine receptors that 
distinguish TH1 from TH2 or chemokine receptors or integrins that indicate 
preferential patterns of homing).

o  Assessment of reagents that can identify newly recognized populations of 
regulatory T cells (e.g., Valpha24JalphaQ bearing invariant T cells) which 
appear to be altered in autoimmune disease.

o  Identification and evaluation of cytokine and cytokine receptor 
polymorphisms and analysis for genetic linkage to disease. 

o  Immune mechanisms of vaccines. Studies to define the underlying mechanisms 
of protection induced by vaccines against infectious diseases, including 
investigation of the specificity and kinetics of cellular and antibody 
responses, Th1/Th2 and cytotoxic T cell characterization, and immune memory.

o  Use of high throughput technologies (e.g., chip technology using expressed 
sequence tags) to identify and evaluate genes activated in disease sites.

o  Identification of useful surrogate markers by correlation of the above 
parameters with disease activity and/or response to intervention or vaccine.

o  Comparison of immune parameters from samples from peripheral blood with 
those from sites of disease, i.e., do peripheral blood samples provide useful 

o  Assessment for the presence of molecular evidence (e.g., using PCR probes) 
of potential causative environmental agents.

o   The molecular and cellular mechanisms by which lymphocytes, macrophages, 
neutrophils, antibodies, cytokines and complement contribute to successful 
immunotherapy for chronic inflammatory diseases.

The areas outlined above are not intended to be all-inclusive.

NOTE: Clinical trials of drug treatments (e.g., antibiotics or antiviral 
drugs) for infectious diseases (e.g., Lyme Disease), and vaccines and 
drug/immunomodulatory treatment for HIV/AIDS are NOT eligible for support 
under this RFA. Applicants are strongly encouraged to contact program staff 
listed under WHERE TO SEND INQUIRIES well in advance of the anticipated 
application submission date to allow staff to assess responsiveness to this 
RFA and provide appropriate guidance as needed.  


This RFA will use the NIH individual research project grant (R01) award. The 
total requested project period for an application submitted in response to 
this RFA may not exceed four years. Some sponsoring Institutes may 
administratively limit the duration of award. The applicant will be solely 
responsible for planning, directing, and executing the proposed project. This 
RFA is a one-time solicitation. Future unsolicited, competing-continuation 
applications based on this project will compete with all investigator-
initiated applications and will be reviewed according to the customary peer 
review procedures.  Applications that are not funded in the competition 
described in this RFA may be resubmitted as NEW investigator-initiated 
applications using the standard receipt dates for NEW applications described 
in the instructions to the PHS 398 application. 

Amended applications will be accepted for Hyperaccelerated Review/Award ONLY 
if invited by NIH.  Applicants with minor or easily corrected problems will be 
invited to submit an abbreviated amendment (5 page limit and one time only), 
which directly addresses the questions and concerns raised in the initial 

This RFA uses just-in-time concepts.  It also uses the modular budgeting 
format. (see https://grants.nih.gov/grants/funding/modular/modular.htm).   
Specifically, if the investigator is submitting an application with direct 
costs in each year of $250,000 or less, use the modular budget format.    This 
program does not require cost sharing as defined in the current NIH Grants 
Policy Statement at 

This RFA uses just-in-time concepts. Applicants must not exceed a limit of 
$250,000 direct costs per year and modular grant procedures should be used. 
(See https://grants.nih.gov/grants/funding/modular/modular.htm). Because the 
nature and scope of the proposed research will vary from application to 
application, it is anticipated that the size and duration of each award will 
also vary. This program does not require cost sharing as defined in the 
current NIH Grants Policy Statement at 


The participating Institutes intend to commit approximately $2,225,000 in FY 
2004 to fund 5 to 7 new grants for ancillary studies of immunomodulatory 
interventions for immune system mediated diseases clinical trials and of 
vaccine clinical trials for non-HIV/AIDS infectious diseases. NIAID intends to 
commit an additional $2,000,000 in FY 2004 to fund 5 to 8 new grants for 
ancillary studies of vaccine clinical trials for the prevention and treatment 
NIAID Category A, B and C agents of bioterrorism and non-HIV/AIDS emerging/re-
emerging infectious diseases.
Although the financial plans of the IC(s) provide support for this program, 
awards pursuant to this RFA are contingent upon the availability of funds and 
the receipt of a sufficient number of meritorious applications. At this time, 
it is not known if this RFA will be reissued. 


The applicant may submit (an) application(s) if the institution has any of the 
following characteristics:

o For-profit or non-profit organizations
o Public or private institutions, such as universities, colleges, hospitals, 
and laboratories
o Units of State and local governments
o Eligible agencies of the Federal government
o Domestic or foreign institutions/organizations


Any individual with the skills, knowledge, and resources necessary to carry 
out the proposed research is invited to work with their institution to develop 
an application for support. Individuals from underrepresented racial and 
ethnic groups as well as individuals with disabilities are always encouraged 
to apply for NIH programs.


1.  Application:
The research plan should be limited to 15 pages.  In addition to the specific 
aims, background and significance, preliminary studies, and research design 
and methods (Sections A to D), the research plan must include a justification 
for why the proposed studies require the use of patients in the parent 
clinical trial as opposed to using patients with the same disease state but 
not in a trial. The manner in which immunological parameters will be related 
to the clinical outcomes in the main study should also be discussed.

Methods of data analysis and power calculations must be included, as well as a 
justification for the required sample size.  A restatement of the sample size 
calculations from the parent clinical trial is insufficient.  If appropriate 
to your application, discuss whether it is necessary to perform the 
mechanistic studies on all patients enrolled in the parent trial or whether a 
sub-sample would be sufficient.  The plan must also include a discussion of 
the statistical procedures that will be used to analyze the data. It is 
strongly recommended that a statistician be part of the research team and 
active in preparation of the proposal.

2. Appendix:

Appendix A should contain the following clearly labeled materials:
o  parent clinical trial protocol
o  investigator’s brochure, if applicable, for the parent clinical trial
o  consent forms for both the parent clinical trial and the mechanistic 
studies, if different 
o  Institutional Review Board (IRB) approval or the parent clinical trial and 
ancillary studies, if completed (Note: IRB approval is not required at the 
time of submission of the application)
o  written agreement for conduct of the mechanistic studies from parent 
clinical trial sponsors, IND holders, and PI of the parent clinical trial.

The protocol and the investigators' brochure for the parent clinical trial 
should be included with the application as part of the human subjects' 
section. Inclusion of the complete clinical protocol within the PHS 398 grant 
application is intended to simplify the application process by eliminating the 
need to duplicate protocol details in the Research Plan section. NIH will 
treat as confidential any scientific, preclinical, clinical, or formulation 
data and information that the sponsor of the parent clinical trial deems to be 
proprietary and confidential.

IRB approval of the informed consent form(s) is not required at the time of 
submission of the application. However, drafts of informed consent form(s) for 
the parent clinical trial and the mechanistic studies, if different, must be 
included as part of Apendix A. While drafts of the parent clinical trial 
consent forms at all participating sites are not required, it would be useful 
to include them if they are available.  It is recommended that applications 
submitted under this program have clear language in the informed consent 
form(s) that distinguishes mechanistic studies from the clinical trials with 
which they are linked. It is also recommended that the following items be 
clarified: (1) additional blood or tissue that will be collected as part of 
the mechanistic study; (2) the right of the subjects to refuse to participate 
in the mechanistic study and still participate in the clinical trial; and (3) 
no charges to the subject for participation in the mechanistic studies. Any 
incentives provided to subjects to participate in the mechanistic studies (if 
in addition to those under the parent trial) should be clearly described and 

In order to ensure coordination between the mechanistic studies and the parent 
clinical trial, the clinical trial principal investigator and his or her 
academic institution, the sponsor of the parent clinical trial (including drug 
companies, if applicable), and the holder of the IND, if not one of the above, 
must provide written agreement for the conduct of the mechanistic studies as 
presented in the application. 

Prior to award, the applicant must provide to the funding institute a 
memorandum of understanding signed by the applicant, an appropriate 
representative of the applicant institution, the principal investigator of the 
parent clinical trial and his or her academic institution, an appropriate 
representative of the sponsor of the parent clinical trial and holder of the 
IND, if applicable and not one of the above.  This memorandum will confirm 
agreement among the various parties and will outline the terms and conditions 
of the agreement in the following areas: 1) ownership, analysis, access, and 
release of data from the mechanistic studies; 2) access to the data from the 
parent clinical trial (how/when) that is needed to analyze the mechanistic 
studies, including procedures for prevention of unblinding of the parent 
trial; 3) documentation of quality assurance procedures for both the parent 
clinical trial and the mechanistic studies, and documentation of Data and 
Safety Monitoring procedures for the parent clinical trial, especially for 
efficacy trials; 4) ownership of intellectual property developed by the 
mechanistic studies; and 5) publication of the mechanistic study results. 

When clinical studies or trials are a component of the research proposed, 
NIAID policy requires that studies be monitored commensurate with the degree 
of potential risk to study subjects and the complexity of the study. AN 
UPDATED NIAID policy was published in the NIH Guide on July 8, 2002 and is 
available at: 
The full policy, including terms and conditions of award, is 
available at: http://www.niaid.nih.gov/ncn/pdf/clinterm.pdf.

3. Summary Report:

To assist in the overall evaluation of the research program, the Principal 
Investigators of grants funded under this RFA will be asked to provide a brief 
(1-2 pages) summary report one year following the end of the project period.  
The reports will summarize the major scientific knowledge gained and identify 
other substantive outcomes such as publications, patents, and new grants, 
contracts, or research studies based on the work supported under this RFA. 


We encourage inquiries concerning this RFA and welcome the opportunity to 
answer questions from potential applicants. Inquiries may fall into three 
areas: scientific research, peer review, and financial or grants management 

o Direct questions about scientific/research issues to:

Kristy Kraemer, Ph.D.
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases
Room 3043, MSC-6601
6610 Rockledge Drive
Bethesda, MD 20892-6601
(Express Mail: 20817)
Phone: 301-496-5598
Fax:   301-480-0693
e-mail: kk187y@nih.gov

Susana A. Serrate-Sztein, M.D.
Rheumatic Diseases Program
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Room 5AS-25E, MSC-6500
45 Center Drive
Bethesda, MD  20892-6500
Phone: 301-594-5032
FAX:   301-480-4543
e-mail: ss86e@nih.gov

Beena Akolkar, Ph.D.
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Room 681
6707 Democracy Boulevard
Bethesda, MD 20892
Phone: 301-594-8812
FAX:   301-480-3503
e-mail: ba92i@nih.gov

Ursula Utz, Ph.D.
National Institute of Neurological Disorders and Stroke
Room 234, MSC-2134
6001 Executive Boulevard
Bethesda, MD 20892-2134
Phone: 301-496-1431
FAX:  301-480-2424
e-mail: uu1p@nih.gov

Dennis F. Mangan, Ph.D.
Immunology and Immunotherapy Program
National Institute of Dental and Craniofacial Research
Room 4AN-Suite 18, MSC-6402
45 Center Drive
Bethesda, MD  20892-6402
Phone: (301) 594-2421
FAX: (301) 480-8318
e-mail: dm38q@nih.gov

o Direct questions about peer review issues to:

Samuel C. Edwards, Ph.D.
Immunological Sciences Initial Review Group
Center for Scientific Review
Room 4200, MSC-7812
6701 Rockledge Drive
Bethesda, MD  20892-7812
(overnight carrier - FEDEX, UPS, Airborne, etc.)  20817
Phone: 301-435-1152
FAX:   301-480-4042
email: se83s@nih.gov

o Direct questions about financial or grants management matters to:

Ann White-Devine
Division of Extramural Activities  
National Institute of Allergy and Infectious Diseases  
Room 2118, MSC-7614
6700-B Rockledge Drive
Bethesda, MD 20892-7614  
Phone: 301-402-5601
FAX:   301-480-3780
e-mail:  ad22x@nih.gov 


Prospective applicants are asked to submit, at least one month prior to the 
anticipated application submission date, a letter of intent that includes the 
following information:

o Descriptive title of the proposed research
o Name, address, and telephone number of the Principal Investigator
o Names of other key personnel
o Participating institutions
o Number and title of this RFA

Although a letter of intent is not required, is not binding, and does not 
enter into the review of a subsequent application, the information that it 
contains allows NIH staff to estimate the potential review workload and plan 
the review.

The letter of intent is to be sent one month prior to the application receipt 
date to Dr. Edwards at the address listed under INQUIRIES.


Applications must be prepared using the PHS 398 research grant application 
instructions and forms (rev. 5/2001).  Applications must have a DUN and 
Bradstreet (D&B) Data Universal Numbering System (DUNS) number as the 
Universal Identifier when applying for Federal grants or cooperative 
agreements. The DUNS number can be obtained by calling (866) 705-5711 or 
through the web site at http://www.dunandbradstreet.com/. The DUNS number 
should be entered on line 11 of the face page of the PHS 398 form.  The PHS 
398 document is available at 
https://grants.nih.gov/grants/funding/phs398/phs398.html in an interactive 
format.  For further assistance contact GrantsInfo, Telephone (301) 710-0267, 
Email: GrantsInfo@nih.gov.
up to $250,000 per year in direct costs must be submitted in a modular grant 
format. The modular grant format simplifies the preparation of the budget in 
these applications by limiting the level of budgetary detail. Applicants 
request direct costs in $25,000 modules. Section C of the research grant 
application instructions for the PHS 398 (rev. 5/2001) at 
https://grants.nih.gov/grants/funding/phs398/phs398.html includes step-by-step 
guidance for preparing modular grants. Additional information on modular 
grants is available at 

USING THE RFA LABEL: The RFA label available in the PHS 398 (rev. 5/2001) 
application form must be affixed to the bottom of the face page of the 
application. Type the RFA number (RFA-AI-04-001) on the label. Failure to use 
this label could result in delayed processing of the application such that it 
may not reach the review committee in time for review. In addition, the RFA 
number (RFA-AI-04-001) must be typed on line 2 of the face page of the 
application form and the YES box must be marked. The RFA label is also 
available at: https://grants.nih.gov/grants/funding/phs398/label-bk.pdf.

SENDING AN APPLICATION TO THE NIH: Submit a signed, typewritten original of 
the application, including the Checklist, and five (5) signed, photocopies, in 
one package to:

Center for Scientific Review  
National Institutes of Health  
6701 Rockledge Drive, Room 1040, MSC 7710  
Bethesda, MD  20892-7710  
Bethesda, MD  20817 (for express/courier service) 

Applications must be received by the 9th of each month. If the ninth of the 
month falls on a weekend day or Federal Holiday, then the receipt date is 
advanced to the next business day. The application must not arrive more than 
two days prior to the receipt date. Applications, which are received after the 
9th, will automatically be processed the following month.  Applications not 
received as a single package on the receipt date or not conforming to the 
instructions contained in PHS 398 (rev. 5/2001) Application Kit (as modified 
in, and superseded by, the special instructions below, for the purposes of 
this RFA), will be judged non-responsive and will be returned to the 

APPLICATION PROCESSING:  Applications must be received by the application 
receipt date listed in the heading of this RFA.  If an application is received 
after that date, it will be returned to the applicant without review.

The Center for Scientific Review (CSR) will not accept any application in 
response to this RFA that is essentially the same as one currently pending 
initial review, unless the applicant withdraws the pending application. 
However, when a previously unfunded application, originally submitted as an 
investigator-initiated application, is to be submitted in response to an RFA, 
it is to be prepared as a NEW application. That is the application for the RFA 
must not include an Introduction describing the changes and improvements made, 
and the text must not be marked to indicate the changes from the previous 
unfunded version of the application. 

Although there is no immediate acknowledgement of the receipt of an 
application, applicants are generally notified of the review and funding 
assignment within 8 weeks.


Upon receipt, applications will be reviewed for completeness by the CSR and 
responsiveness by the NIAID. 

Incomplete and/or non-responsive applications will be returned to the 
applicant without further consideration.

Applications that are complete and responsive to the RFA will be evaluated for 
scientific and technical merit by an appropriate peer review group convened by 
the NIH in accordance with the review criteria stated below. As part of the 
initial merit review, all applications will:

o Undergo a selection process in which only those applications deemed to have 
the highest scientific merit, generally the top half of applications under 
review, will be discussed and assigned a priority score
o Receive a written critique
o Receive a second level review by the National Advisory Council(s) of the 
assigned Institutes.


The goals of NIH-supported research are to advance our understanding of 
biological systems, improve the control of disease, and enhance health. In the 
written comments, reviewers will be asked to discuss the following aspects of 
the application in order to judge the likelihood that the proposed research 
will have a substantial impact on the pursuit of these goals:

o Significance
o Approach
o Innovation
o Investigator
o Environment

The scientific review group will address and consider each of these criteria 
in assigning the application’s overall score, weighting them as appropriate 
for each application. The application does not need to be strong in all 
categories to be judged likely to have major scientific impact and thus 
deserve a high priority score. For example, an investigator may propose to 
carry out important work that by its nature is not innovative but is essential 
to move a field forward.

SIGNIFICANCE: Does this study address an important problem? If the aims of the 
application are achieved, how will scientific knowledge be advanced? What will 
be the effect of these studies on the concepts or methods that drive this 

APPROACH: Are the conceptual framework, design, methods, and analyses 
adequately developed, well-integrated, and appropriate to the aims of the 
project? Does the applicant acknowledge potential problem areas and consider 
alternative tactics?

INNOVATION: Does the project employ novel concepts, approaches or methods? Are 
the aims original and innovative? Does the project challenge existing 
paradigms or develop new methodologies or technologies?

INVESTIGATOR: Is the investigator appropriately trained and well-suited to 
carry out this work? Is the work proposed appropriate to the experience level 
of the principal investigator and other researchers (if any)?

ENVIRONMENT: Does the scientific environment in which the work will be done 
contribute to the probability of success? Do the proposed experiments take 
advantage of unique features of the scientific environment or employ useful 
collaborative arrangements? Is there evidence of institutional support?

subjects and protections from research risk relating to their participation in 
the proposed research will be assessed. (See criteria included in the section 
on Federal Citations, below)
to include subjects from both genders, all racial and ethnic groups (and 
subgroups), and children as appropriate for the scientific goals of the 
research.  Plans for the recruitment and retention of subjects will also be 
evaluated. (See Inclusion Criteria in the sections on Federal Citations, 

be used in the project, the five items described under Section f of the PHS 
398 research grant application instructions (rev. 5/2001) will be assessed.  


SHARING RESEARCH DATA:  Applicants requesting more than $500,000 in direct 
costs in any year of the proposed research are expected to include a data 
sharing plan in their application. The reasonableness of the data sharing plan 
or the rationale for not sharing research data will be assessed by the 
reviewers. However, reviewers will not factor the proposed data-sharing plan 
into the determination of scientific merit or priority score. (See 
instructions and URL to policy in the Federal Citations, below.)

BUDGET:  The reasonableness of the proposed budget and the requested period of 
support in relation to the proposed research.


Letter of Intent Receipt Date:     One month before application receipt date.
Application Receipt Date:          9th of each month.
Peer Review Date:                  4-6 weeks after receipt date
Council Review Date:               Special Electronic Council
Earliest Anticipated Start Date:   13 weeks after receipt of application.


Award criteria that will be used to make award decisions include:

o Scientific merit of the proposed project as determined by peer review
o Availability of funds
o Programmatic priorities


HUMAN SUBJECTS PROTECTION: Federal regulations (45CFR46) require that 
applications and proposals involving human subjects must be evaluated with 
reference to the risks to the subjects, the adequacy of protection against 
these risks, the potential benefits of the research to the subjects and 
others, and the importance of the knowledge gained or to be gained.  

DATA AND SAFETY MONITORING PLAN: Data and safety monitoring is required for 
all types of clinical trials, including physiologic, toxicity, and dose-
finding studies (phase I); efficacy studies (phase II), efficacy, 
effectiveness and comparative trials (phase III). The establishment of data 
and safety monitoring boards (DSMBs) is required for multi-site clinical 
trials involving interventions that entail potential risk to the participants. 
(NIH Policy for Data Safety and Monitoring, NIH Guide for Grants and 
Contracts, June 12, 1998: 

SHARING RESEARCH DATA:  Starting with the October 1, 2003 receipt date, 
investigators submitting an NIH application seeking more than $500,000 or more 
in direct costs in any single year are expected to include a plan for data 
sharing or state why this is not possible.  
https://grants.nih.gov/grants/policy/data_sharing Investigators should seek 
guidance from their institutions, on issues related to institutional policies, 
local IRB rules, as well as local, state and Federal laws and regulations, 
including the Privacy Rule. Reviewers will consider the data sharing plan but 
will not factor the plan into the determination of the scientific merit or the 
priority score.

the NIH that women and members of minority groups and their sub-populations 
must be included in all NIH-supported clinical research projects unless a 
clear and compelling justification is provided indicating that inclusion is 
inappropriate with respect to the health of the subjects or the purpose of the 
research. This policy results from the NIH Revitalization Act of 1993 (Section 
492B of Public Law 103-43).

All investigators proposing clinical research should read the AMENDMENT "NIH 
Guidelines for Inclusion of Women and Minorities as Subjects in Clinical 
Research - Amended, October, 2001," published in the NIH Guide for Grants and 
Contracts on October 9, 2001 
a complete copy of the updated Guidelines are available at 

The amended policy incorporates: the use of an NIH definition of clinical 
research; updated racial and ethnic categories in compliance with the new OMB 
standards; clarification of language governing NIH-defined Phase III clinical 
trials consistent with the new PHS Form 398; and updated roles and 
responsibilities of NIH staff and the extramural community. The policy 
continues to require for all NIH-defined Phase III clinical trials that: a) 
all applications or proposals and/or protocols must provide a description of 
plans to conduct analyses, as appropriate, to address differences by 
sex/gender and/or racial/ethnic groups, including subgroups if applicable; and 
b) investigators must report annual accrual and progress in conducting 
analyses, as appropriate, by sex/gender and/or racial/ethnic group 

The NIH maintains a policy that children (i.e., individuals under the age of 
21) must be included in all human subjects research, conducted or supported by 
the NIH, unless there are scientific and ethical reasons not to include them. 
This policy applies to all initial (Type 1) applications submitted for receipt 
dates after October 1, 1998.

All investigators proposing research involving human subjects should read the 
"NIH Policy and Guidelines" on the inclusion of children as participants in 
research involving human subjects that is available at 

requires education on the protection of human subject participants for all 
investigators submitting NIH proposals for research involving human subjects. 
This policy announcement is in the NIH Guide for Grants and Contracts 
Announcement, dated June 5, 2000, at 

HUMAN EMBRYONIC STEM CELLS (hESC): Criteria for federal funding of research on 
hESCs can be found at http://stemcells.nih.gov/index.asp and at 
https://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-005.html. Only 
research using hESC lines that are registered in the NIH Human Embryonic Stem 
Cell Registry will be eligible for Federal funding (see 
http://stemcells.nih.gov/registry/). It is the responsibility of the applicant 
to provide, in the project description and elsewhere in the application as 
appropriate the official NIH identifier(s) for the hESC line(s)to be used in 
the proposed research. Applications that do not provide this information will 
be returned without review. 

Office of Management and Budget (OMB) Circular A-110 has been revised to 
provide public access to research data through the Freedom of Information Act 
(FOIA) under some circumstances. Data that are (1) first produced in a project 
that is supported in whole or in part with Federal funds and (2) cited 
publicly and officially by a Federal agency in support of an action that has 
the force and effect of law (i.e., a regulation) may be accessed through FOIA. 
It is important for applicants to understand the basic scope of this 
amendment. NIH has provided guidance at 

Applicants may wish to place data collected under this PA in a public archive, 
which can provide protections for the data and manage the distribution for an 
indefinite period of time. If so, the application should include a description 
of the archiving plan in the study design and include information about this 
in the budget justification section of the application. In addition, 
applicants should think about how to structure informed consent statements and 
other human subjects procedures given the potential for wider use of data 
collected under this award.

Department of Health and Human Services (DHHS) issued final modification to 
the “Standards for Privacy of Individually Identifiable Health Information”, 
the “Privacy Rule,” on August 14, 2002. The Privacy Rule is a federal 
regulation under the Health Insurance Portability and Accountability Act 
(HIPAA) of 1996 that governs the protection of individually identifiable 
health information, and is administered and enforced by the DHHS Office for 
Civil Rights (OCR). Those who must comply with the Privacy Rule (classified 
under the Rule as “covered entities”) must do so by April 14, 2003 (with the 
exception of small health plans which have an extra year to comply).

Decisions about applicability and implementation of the Privacy Rule reside 
with the researcher and his/her institution. The OCR website 
(http://www.hhs.gov/ocr/) provides information on the Privacy Rule, including 
a complete Regulation Text and a set of decision tools on “Am I a covered 
entity?” Information on the impact of the HIPAA Privacy Rule on NIH processes 
involving the review, funding, and progress monitoring of grants, cooperative 
agreements, and research contracts can be found at 

URLs IN NIH GRANT APPLICATIONS OR APPENDICES: All applications and proposals 
for NIH funding must be self-contained within specified page limitations. 
Unless otherwise specified in an NIH solicitation, Internet addresses (URLs) 
should not be used to provide information necessary to the review because 
reviewers are under no obligation to view the Internet sites. Furthermore, we 
caution reviewers that their anonymity may be compromised when they directly 
access an Internet site.

HEALTHY PEOPLE 2010: The Public Health Service (PHS) is committed to achieving 
the health promotion and disease prevention objectives of "Healthy People 
2010," a PHS-led national activity for setting priority areas. This PA is 
related to one or more of the priority areas. Potential applicants may obtain 
a copy of "Healthy People 2010" at http://www.health.gov/healthypeople.


This program is described in the Catalogue of Federal Domestic Assistance at 
http://www.cfda.gov/ in the following citations: No. 93.855, Immunology, 
Allergy, and Transplantation Research and No. 93.856, Microbiology and 
Infectious Diseases Research, NIAID; No. 93.847, Diabetes, Endocrinology and 
Metabolism Research, No. 93.848, Digestive Diseases and Nutrition Research, 
and No. 93.849, Kidney Diseases, Urology and Hematology Research, NIDDK; No. 
93.866, Arthritis, Musculoskeletal and Skin Diseases Research, NIAMS; 
No.93.853, Extramural Research Programs in the Neurosciences and Neurological 
Diseases, NINDS. Awards are made under authorization of Sections 301 and 405 
of the Public Health Service Act as amended (42 USC 241 and 284) and 
administered under NIH grants policies and Federal Regulations 42 CFR 52 and 
45 CFR Parts 74 and 92. This program is not subject to the intergovernmental 
review requirements of Executive Order 12372 or Health Systems Agency review.

The NIH Grants Policy Statement is available at 
https://grants.nih.gov/grants/policy/policy.htm. This document includes general 
information about the grant application and review process; information on the 
terms and conditions that apply to NIH Grants and cooperative agreements; and 
a listing of pertinent offices and officials at the NIH. All awards are 
subject to the terms and conditions, cost principles, and other considerations 
described in the NIH Grants Policy Statement. 

The PHS strongly encourages all grant recipients to provide a smoke-free 
workplace and discourage the use of all tobacco products. In addition, Public 
Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain 
facilities (or in some cases, any portion of a facility) in which regular or 
routine education, library, day care, health care, or early childhood 
development services are provided to children. This is consistent with the PHS 
mission to protect and advance the physical and mental health of the American 

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.